November 30, 2016 - By Marie Mckinney · 0 Comments
The stock of Cytomx Therapeutics Incorporated (NASDAQ:CTMX) registered a decrease of 7.34% in short interest. CTMX’s total short interest was 935,400 shares in November as published by FINRA. Its down 7.34% from 1.01M shares, reported previously. With 67,800 shares average volume, it will take short sellers 14 days to cover their CTMX’s short positions. The short interest to Cytomx Therapeutics Incorporated’s float is 4.48%. About 51,636 shares traded hands. CytomX Therapeutics Inc (NASDAQ:CTMX) has declined 16.04% since April 27, 2016 and is downtrending. It has underperformed by 21.26% the S&P500.
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The company has a market cap of $392.24 million. The Firm is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It currently has negative earnings. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Out of 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytomX Therapeutics has been the topic of 3 analyst reports since November 2, 2015 according to StockzIntelligence Inc. Jefferies initiated the shares of CTMX in a report on Monday, November 2 with “Buy” rating. The firm has “Outperform” rating by Cowen & Co given on Monday, November 2. Oppenheimer initiated CytomX Therapeutics Inc (NASDAQ:CTMX) rating on Monday, November 2. Oppenheimer has “Outperform” rating and $17 price target.
CytomX Therapeutics, Inc., incorporated on October 16, 2010, is an oncology-focused biopharmaceutical company. The Firm is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. The Firm uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. The Company’s Probody therapeutics are designed to take advantage of the conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. When a Probody therapeutic enters a tumor, it encounters proteases, which are enzymes that cleave proteins and are active primarily in the tumor microenvironment. The proteases in the tumor cleave the linker, releasing the mask and allowing the antibody to attack the tumor. The Company’s Probody candidates are designed to be produced as fully recombinant antibody prodrugs.
More news for CytomX Therapeutics Inc (NASDAQ:CTMX) were recently published by: Marketwatch.com, which released: “CytomX Therapeutics Inc.” on September 01, 2015. Quotes.Wsj.com‘s article titled: “News CytomX Therapeutics Inc.CTMX” and published on September 12, 2015 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney